Tag Archives: NASDAQ:AVRO

Mizuho Securities Reaffirms Their Buy Rating on Avrobio (AVRO)

Mizuho Securities analyst Difei Yang maintained a Buy rating on Avrobio (AVRO – Research Report) on September 12 and set a price target of $35.00. The company’s shares closed last Monday at $15.53. According to TipRanks.com, Yang is currently ranked

Avrobio (AVRO) Gets a Hold Rating from H.C. Wainwright

H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Hold rating on Avrobio (AVRO – Research Report) today and set a price target of $13.00. The company’s shares closed last Wednesday at $16.75. According to TipRanks.com, Chattopadhyay is a 5-star analyst with

Analysts Offer Insights on Healthcare Companies: Avrobio (NASDAQ: AVRO) and SAGE Therapeutics (NASDAQ: SAGE)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Avrobio (AVRO – Research Report) and SAGE Therapeutics (SAGE – Research Report). Avrobio (AVRO) Mizuho Securities analyst Difei Yang reiterated a Buy rating on Avrobio

Analysts Offer Insights on Healthcare Companies: Avrobio (NASDAQ: AVRO), Dicerna Pharma (NASDAQ: DRNA) and Daré Bioscience (NASDAQ: DARE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avrobio (AVRO – Research Report), Dicerna Pharma (DRNA – Research Report) and Daré Bioscience (DARE – Research Report) with bullish sentiments. Avrobio

H.C. Wainwright Downgrades Avrobio (AVRO) to Hold

Avrobio (AVRO – Research Report) received a Hold rating and a $13.00 price target from H.C. Wainwright analyst Debjit Chattopadhyay today. The company’s shares closed last Monday at $16.53. According to TipRanks.com, Chattopadhyay is currently ranked with no stars on

Cowen & Co. Keeps Their Buy Rating on Avrobio (AVRO)

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Avrobio (AVRO – Research Report) yesterday. The company’s shares closed last Monday at $10.08, close to its 52-week low of $9.95. According to TipRanks.com, Baral is a 4-star analyst